Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $37 Price Target

Oppenheimer analyst Kostas Biliouris has reiterated an 'Outperform' rating on Sarepta Therapeutics (NASDAQ: SRPT) and maintained a price target of $37 for the stock.